Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : Novavax Statement on Takeda Agreement to Provide 150 Million Doses of NVX-CoV2373 to the Government of Japan

09/13/2021 | 10:09am EDT

Takeda Pharmaceutical Company Limited announced that it had finalized an agreement with the government of Japan'sMinistry of Health, Labour and Welfare (MHLW) for the purchase of 150 million doses of Novavax' recombinant nanoparticle COVID-19 vaccine candidate, NVX-CoV2373 (TAK-019 in Japan).

'This agreement demonstrates confidence in and ongoing global demand for NVX-CoV2373 as a significant additional option to control the COVID-19 pandemic,' said Stanley C. Erck, President and Chief Executive Officer, Novavax. 'Our important partnership with Takeda is an example of the global collaborations that will be required to stay ahead of the virus and its variants.'

The announcement follows a recent update from MHLW on its ongoing efforts to secure coronavirus vaccine for the citizens of Japan. These efforts include vaccine procurement by Takeda based on technology transfer from Novavax, with Takeda in the process of manufacturing implementation at its facility.

Distribution of Novavax' vaccine in Japan by Takeda is expected to begin in early 2022. Novavax and Takeda previously announced a licensing agreement and are collaborating on manufacturing, clinical development and regulatory activities in Japan. Takeda anticipates the capacity to manufacture more than 250 million doses of Novavax' COVID-19 vaccine per year.

Contact:

21 Firstfield Road

Gaithersburg

MD 20878

T: (240) 268-2000

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
NOVAVAX, INC. -0.27% 134.99 Delayed Quote.21.06%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -0.09% 3184 End-of-day quote.-15.21%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
10/26Phathom Pharmaceuticals Launches 5 Million Share Offering
MT
10/21TAKEDA PHARMACEUTICAL : to Hold Second Quarter FY2021 Earnings Conference Calls
PU
10/20NOVAVAX : Dismisses Media Report on COVID-19 Vaccine Quality, Production Delays; Shares Do..
MT
10/20NOVAVAX : Refutes Media Report on its COVID-19 Vaccine Quality, Production Delays
MT
10/18WAVE LIFE SCIENCES : Takeda Pharmaceutical Partially Amend Central Nervous System Collabor..
MT
10/18Wave Life Sciences Ltd. Announces an Amendment to its Ongoing Collaboration with Takeda..
CI
10/18CALITHERA BIOSCIENCES : Buys Two Clinical-Stage Assets from Takeda to Boost Oncology Pipel..
MT
10/18Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from ..
CI
10/18Calithera Agrees to Acquire 2 Clinical-Stage Assets from Takeda Pharma
DJ
10/14TAKEDA PHARMACEUTICAL : Working With Immusoft to Develop B-Cell Therapies for Rare Neurome..
MT
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 398 B 29 801 M 29 801 M
Net income 2022 249 B 2 181 M 2 181 M
Net Debt 2022 3 258 B 28 569 M 28 569 M
P/E ratio 2022 20,3x
Yield 2022 5,65%
Capitalization 5 007 B 43 832 M 43 911 M
EV / Sales 2022 2,43x
EV / Sales 2023 2,29x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 3 184,00 JPY
Average target price 4 372,86 JPY
Spread / Average Target 37,3%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-15.21%44 084
JOHNSON & JOHNSON5.32%431 938
ROCHE HOLDING AG15.61%338 364
NOVO NORDISK A/S59.69%243 351
PFIZER, INC.17.22%241 929
ELI LILLY AND COMPANY47.15%222 158